Furthering its goal to grow the reach of its mRNA vaccines and guard against future pandemics, Moderna cleared a key ...

Leerink Partners analyst David Risinger maintained a Sell rating on Moderna (MRNA – Research Report) yesterday and set a price target of ...

Advancements in mRNA vaccine technology are reshaping medicine, addressing challenges and expanding applications from ...

The FDA will remove industry representatives from advisory committees and replace them with patients and caregivers ...

US mRNA specialist Moderna (Nasdaq: MRNA) has announced that its manufacturing facility in the UK has been granted a manufacturer’s license by the Medicines and Healthcare products Regulatory Agency ...

The most recent trading session ended with Moderna (MRNA) standing at $24.73, reflecting a -1.85% shift from the previouse trading day's closing. The stock's performance was behind the S&P 500's daily ...

What Happened? A number of stocks fell in the afternoon session after Federal Reserve Chair Jerome Powell signaled a cautious ...

The U.S. government continues to end contracts related to the $5 billion Project NextGen initiative, this time terminating ...

In a report released today, Michael Yee from Jefferies maintained a Hold rating on Moderna (MRNA – Research Report), with a price target of ...

Arexvy and Abrysvo are approved to prevent RSV-associated lower respiratory tract disease in adults aged 50 to 59 and 18 to ...

The Advisory Committee on Immunization Practices voted Wednesday to recommend lowering the age at which adults can get a ...

With petrol cars being banned in five years time is there still room for a £227,570 V6-powered supercar? Express reporter ...